-
Product Insights
B-Cell Leukemia Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “B-Cell Leukemia Global Clinical Trials Review, H1, 2016" provides an overview of B-Cell Leukemia clinical trials scenario. This report provides top line data relating to the clinical trials on B-Cell Leukemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Cutaneous T-Cell Lymphoma Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Cutaneous T-Cell Lymphoma Global Clinical Trials Review, H1, 2016" provides an overview of Cutaneous T-Cell Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on Cutaneous T-Cell Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2016" provides an overview of Diffuse Large B-Cell Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on Diffuse Large B-Cell Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Hairy Cell Leukemia Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Hairy Cell Leukemia Global Clinical Trials Review, H1, 2016" provides an overview of Hairy Cell Leukemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hairy Cell Leukemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Hepatocellular Carcinoma Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Hepatocellular Carcinoma Global Clinical Trials Review, H1, 2016" provides an overview of Hepatocellular Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatocellular Carcinoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Indolent Lymphoma Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Indolent Lymphoma Global Clinical Trials Review, H1, 2016" provides an overview of Indolent Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on Indolent Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Basal Cell Carcinoma (Basal Cell Epithelioma) Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Basal Cell Carcinoma (Basal Cell Epithelioma) Global Clinical Trials Review, H1, 2016" provides an overview of Basal Cell Carcinoma (Basal Cell Epithelioma) clinical trials scenario. This report provides top line data relating to the clinical trials on Basal Cell Carcinoma (Basal Cell Epithelioma). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase,...
-
Product Insights
Bile Duct Cancer (Cholangiocarcinoma) Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Bile Duct Cancer (Cholangiocarcinoma) Global Clinical Trials Review, H1, 2016" provides an overview of Bile Duct Cancer (Cholangiocarcinoma) clinical trials scenario. This report provides top line data relating to the clinical trials on Bile Duct Cancer (Cholangiocarcinoma). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Gastrointestinal Stromal Tumor (GIST) Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Gastrointestinal Stromal Tumor (GIST) Global Clinical Trials Review, H1, 2016" provides an overview of Gastrointestinal Stromal Tumor (GIST) clinical trials scenario. This report provides top line data relating to the clinical trials on Gastrointestinal Stromal Tumor (GIST). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Sector Analysis
Immuno-Oncology Strategic Insight: Multi-Indication and Market Size Analysis
GlobalData estimates that the total IO market will be worth approximately $14 billion in 2019, rising to $34 billion by 2024 in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). The main drivers of this growth will come from immune checkpoint inhibitors, which will have sales of approximately $10 billion in 2019, rising to $24 billion by 2024. The highest-selling IO drugs by 2024 will be Opdivo and Keytruda, both PD-1 inhibitors, with sales of approximately $10 billion...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.